

hydrolysable ester thereof, and a pharmaceutically acceptable carrier,

<sup>11</sup>  
~~57~~. A pharmaceutical composition as claimed in claim <sup>10</sup>~~56~~ further comprising a  $\beta$ -lactamase inhibitor.

<sup>12</sup>  
~~58~~. A method of treating bacterial infections in humans and animals which comprises administering a therapeutically effective amount of a compound of claim ~~58~~ or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof to a human or animal.

Remarks


New claim 57 corresponds to original claims 1 and 3. Original claim 3 has been canceled in view of new claim 57. Furthermore, original process claims 39 and 40 have been canceled as well as claim 41 to the intermediates

In view of the above, favorable consideration of claims 57 to 68 on file is respectfully solicited.

Respectfully submitted,

Date:

6/6/95

  
Gezina Holtrust  
Attorney for Applicants  
Reg. No. 28,222

Pfizer Inc.  
Patent Dept., 20th Floor  
235 East 42nd Street  
New York, NY 10017-5755  
(212) 573-7793